Current Edition

NeuroGenetic Pharmaceuticals Awarded $2.5 Million Grant From NIA to Conduct Clinical Trials with NGP 555 to Treat and Prevent Alzheimer’s Disease; Reports Initial Results of Phase 1a Clinical Trial

SAN DIEGO/November 10, 2015 –(BUSINESS WIRE)–NeuroGenetic Pharmaceuticals, Inc. (NGP), a privately held biopharmaceutical company focused on Alzheimer’s disease (AD) therapeutics, has been awarded an R01 grant from the National Institute of Aging (NIA) in the amount of $2.5 million for first in human clinical trials with NGP 555. NGP 555 is a proprietary “first in class” small molecule for the treatment and prevention of Alzheimer’s disease. NGP 555 is an amyloid modulator showing good brain penetration in pre-clinical models and is available in capsules for once daily dosing.
The grant funds pilot clinical trials for Alzheimer’s disease. NGP has completed the Phase 1a double blind, placebo controlled, single ascending dose clinical trial with NGP 555. Five cohorts of young, healthy subjects were dosed with 25 mg – 300 mg. All doses were safe and well-tolerated with dose-dependent plasma exposure. The 14-day Phase 1b multiple ascending dose clinical trial is expected to begin next month.